16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Burkitt Lymphoma Presenting as an Intracardiac Mass: Case Report and Review of Literature

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Patient: Male, 27

          Final Diagnosis: Burkitt lymphoma with intracardiac mass

          Symptoms: Dizziness • fatigue • palpitations • weight loss

          Medication: —

          Clinical Procedure: Catheter-directed thrombolytic therapy with intracardiac infusion of alteplase

          Specialty: Hematology

          Objective:

          Rare disease

          Background:

          Non-neoplastic causes such as infections and thrombi account for most intracardiac masses. Primary tumors such as myxomas and metastasis from breast cancer, lung cancer, or melanomas account for many of the remaining cases. Burkitt lymphoma manifesting as an intracardiac mass is a rare entity, with 21 cases reported in the English literature.

          Case Report:

          We report the case of a man infected with human immunodeficiency virus (HIV) who presented with non-specific cardiac symptoms and was later found to have intracardiac mass caused by Burkitt lymphoma. His rapid decline with unexpected complications was reversed with prompt management. Subsequent to induction, the patient achieved a near complete response with considerable improvement in his condition.

          Conclusions:

          Lymphoma should be considered in the differential diagnosis of intracardiac masses. Associated cardiac symptoms are frequently non-specific and can often be overlooked or underappreciated. Burkitt lymphoma has a short doubling time and an intracardiac lesion can become life-threatening in a matter of days. Early recognition and prompt treatment are crucial to achieving optimal outcomes.

          Related collections

          Most cited references32

          • Record: found
          • Abstract: found
          • Article: not found

          Adult Burkitt leukemia and lymphoma.

          The World Health Organization Classification of Lymphoid Neoplasms identifies Burkitt lymphoma/leukemia as a highly aggressive mature B-cell neoplasm consisting of endemic, sporadic, and immunodeficiency-associated variants. These subtypes share many morphologic and immunophenotypic features, but differences exist in their clinical and geographic presentations. All of these subtypes possess chromosomal rearrangements of the c-myc oncogene, the genetic hallmark of Burkitt lymphoma that contributes to lymphomagenesis through alterations in cell cycle regulation, cellular differentiation, apoptosis, cellular adhesion, and metabolism. Brief-duration, high-intensity chemotherapy regimens containing aggressive central nervous system prophylaxis have had remarkable success in the treatment of this disease, with complete remission rates of 75% to 90% and overall survivals reaching 50% to 70% in adults. Although Burkitt lymphoma cells are extremely chemosensitive, biologically targeted therapies should be developed because current treatment options are suboptimal for patients with poor prognostic features or in the setting of relapsed disease.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Primary cardiac lymphoma: an analysis of presentation, treatment, and outcome patterns.

            Primary cardiac lymphoma (PCL) represents a rare subset of non-Hodgkin lymphoma, characterized by poor outcomes. The authors aimed to construct a framework of known clinical presentations, diagnostic features, disease complications, treatment, and outcomes to improve prognostication. Individual patient data were obtained from defined cases of PCL (1949-2009) and systematically analyzed. The authors report results of a review of 197 cases of PCL, with half of all cases reported since 1995. Survival was affected by 4 factors: immune status, left ventricular involvement, presence of extra-cardiac disease, and arrhythmia. Median overall survival (OS) for immunocompromised and immunocompetent was 3.5 months (m) and not reached, respectively (HR 0.29, 95% CI, 0.13-0.68; P = .004). LV involvement was uncommon (26%) and associated with an OS of only 1 m, whereas patients free of LV involvement had a median OS of 22 m (HR 0.28, 95% CI, 0.12-0.64; P = .002). Patients with extracardiac disease had shorter median OS compared with those without (6 m vs 22 m, HR 0.49, 95% CI, 0.26-0.91; P = .02). Those patients with an arrhythmia of any type had a median OS that was not reached (n = 55), whereas those without rhythm disturbances (n = 41) had median OS of 6 m (HR 0.51, 95% CI, 0.29-0.91; P = .024). Overall response rate to therapy was 84%, with long-term OS over 40%. The current study presents the largest analysis of PCL to date. The data demonstrate that PCL is now more frequently diagnosed premortem and appears to have reasonable response rates. Lack of LV involvement and the presence of arrhythmias are associated with improved survival. Copyright © 2010 American Cancer Society.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Cardiac tumours: diagnosis and management.

                Bookmark

                Author and article information

                Journal
                Am J Case Rep
                Am J Case Rep
                amjcaserep
                The American Journal of Case Reports
                International Scientific Literature, Inc.
                1941-5923
                2016
                03 August 2016
                : 17
                : 553-558
                Affiliations
                [1 ]Department of Medicine, University of Arizona, Banner University Medical Center, Tucson, AZ, U.S.A.
                [2 ]Department of Medicine, Maricopa Integrated Health System, Phoenix, AZ, U.S.A.
                [3 ]Department of Cardiology, Maricopa Integrated Health System, Phoenix, AZ, U.S.A.
                [4 ]Department of Hematology Oncology, Maricopa Integrated Health System, Phoenix, AZ, U.S.A.
                Author notes

                Authors’ Contribution:

                [A]

                Study Design

                [B]

                Data Collection

                [C]

                Statistical Analysis

                [D]

                Data Interpretation

                [E]

                Manuscript Preparation

                [F]

                Literature Search

                [G]

                Funds Collection

                Conflict of interest: None declared

                Corresponding Author: Onyee Chan, e-mail: onyeec@ 123456deptofmed.arizona.edu
                Article
                899022
                10.12659/AJCR.899022
                4973801
                27484990
                a603cd2e-e8cc-4dd2-82b6-b9a1b12ace3e
                © Am J Case Rep, 2016

                This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License

                History
                : 13 April 2016
                : 04 May 2016
                Categories
                Articles

                burkitt lymphoma,heart neoplasms,lymphoma, non-hodgkin

                Comments

                Comment on this article